Dasatinib (Sprycel®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000348
English
Authors' recommendations:
Dasatinib (Sprycel®) for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia in the chronic phase is not recommended for use within NHS Wales. The case for cost effectiveness has not been proven.
Details
Project Status:
Completed
Year Published:
2011
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=185142&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive
- Pyrimidines
- Thiazoles
- Protein Kinase Inhibitors
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.